USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent licensed to Regulus

   USPTO Grants Santaris' Request for Inter-Partes Reexamination of Patent
                             licensed to Regulus

  PR Newswire

  HOERSHOLM, Denmark and SAN DIEGO, Jan. 7, 2013

HOERSHOLM, Denmark and SAN DIEGO, Jan. 7, 2013 /PRNewswire/ -- Santaris Pharma
A/S, a clinical-stage biopharmaceutical company focused on the discovery and
development of RNA-targeted therapies, today announced that the USPTO has
issued an Order granting their request for inter-partes re-examination of US
patent 7,838,504 (the '504 patent), in the name of The Board of Trustees of
the Leland Stanford Junior University, and licensed to Regulus Therapeutics
Inc.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO )

The Order indicates that Santaris's request "establishes a reasonable
likelihood that Santaris will prevail" with respect to the claims under
re-examination. In conjunction with the Order, the USPTO also issued an
Office Action rejecting the re-examined claims.

The '504 patent refers to a method of reducing viral genome amount in a cell
infected with Hepatitis C with an antisense oligonucleotide complementary to
miR-122, and at least one additional agent selected from the group consisting
of an antiviral agent and an interferon.

Henrik Stage, CEO of Santaris Pharma A/S stated: "We are very pleased that
the USPTO has ordered inter-partes re-examination of the '504 patent.
Appropriately reducing the scope of the patent in the U.S., is part of our
worldwide strategy that currently includes opposition proceedings in Europe
and Australia as well."

About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combines the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver LNA-based drug candidates against
RNA targets, both mRNA and microRNA, for a range of diseases including
infectious and inflammatory diseases, cardiometabolic disorders, cancer and
rare genetic disorders. LNA-based drugs are a promising new class of
therapeutics that are enabling scientists to develop drug candidates that
target previously inaccessible clinical pathways. The LNA Drug Platform
overcomes the limitations of earlier antisense and siRNA technologies to
deliver potent single-stranded LNA-based drug candidates across a multitude of
disease states. The unique combination of small size and very high affinity
allows this new class of drug candidates to potently and specifically inhibit
RNA targets in many different tissues without the need for complex delivery
vehicles. The most important features of LNA-based drugs include excellent
specificity providing optimal targeting; increased affinity to targets
providing improved potency; and favorable pharmacokinetic and
tissue-penetrating properties that allow systemic delivery of these drugs
without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S Santaris Pharma A/S is a privately held
clinical-stage biopharmaceutical company focused on the discovery and
development of RNA-targeted therapies. The LNA Drug Platform and Drug
Discovery Engine developed by Santaris Pharma A/S combine the company's
proprietary LNA chemistry with its highly specialized and targeted drug
development capabilities to rapidly deliver potent single-stranded LNA-based
drug candidates across a multitude of disease states. The company's research
and development activities focus on infectious diseases and cardiometabolic
disorders, while partnerships with major pharmaceutical companies include a
range of therapeutic areas including cancer, cardiovascular disease,
infectious and inflammatory diseases, and rare genetic disorders. The company
has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer,
GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent
estate, the company holds exclusive worldwide rights to manufacture, have
manufactured and sell products that contain LNA as an active ingredient for
studies performed with a view to obtaining marketing approval. Santaris Pharma
A/S, founded in 2003, is headquartered in Denmark with operations in the
United States. Please visit www.santaris.com for more information.

Website: http://www.santaris.com
Contact: Henrik Oerum, CSO, Cell: +45-2834-6474, e-mail: hoe@santaris.com,
www.santaris.com
 
Press spacebar to pause and continue. Press esc to stop.